Reports Q4 revenue $2.424M vs $2.322M last year. “2025 was a year of structural change and strategic re-focus for Nuwellis (NUWE),” said John Erb, Chief Executive Officer of Nuwellis. “While full year revenue declined compared to 2024, fourth quarter results reflected stronger utilization trends and meaningful gross margin expansion. Throughout the year, we prioritized operational discipline, refined our commercial focus around the cardiorenal continuum, and strengthened the underlying foundation of the business.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis appoints Goldstein as Director of Clinical Strategy
- Nuwellis Expands Board With New Independent Financial Experts
- Nuwellis appoints McDonald, Emerson to board of directors
- Nuwellis files to sell 4.28M shares of common stock for holders
- Nuwellis Raises Capital and Acquires Rendiatech to Expand